Preliminary SpotLight™ Human Lambda
reagent data to be showcased by GSK at the 16th annual
PEACe Conference
EMERYVILLE, Calif., Sept. 21,
2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq:
CELL), a functional cell biology company, is pleased to announce
that GSK will present data on the SpotLight™ Human Lambda reagent
for the Beacon® platform at the 16th annual Conference on Protein
Expression in Animal Cells, which is being held in Sitges,
Spain from September 24-28, 2023. The goal of the PEACe
Conference is to continue the tradition of bringing together
scientists from academia and industry to share knowledge in the
field of recombinant protein expression.
Molly Robinson, a senior
scientist with GSK, will present data demonstrating how the
SpotLight Human Fc, SpotLight Human Kappa and SpotLight Human
Lambda reagents can be used in cell line development productivity
assays on the Beacon platform. In this study, as an early access
PhenomeX customer, GSK screened clones secreting IgG Lambda light
chain monoclonal antibodies and clones secreting bispecific
lambda-kappa antibodies. Additionally, the GSK team was able to
characterize a variety of molecular formats using the library of
SpotLight reagents, and they are excited to continue using these
reagents to investigate complex molecular candidates.
PhenomeX's fluorescent SpotLight reagents, which are
non-destructive and certified as animal- component free, allow
early productivity and product quality screens to be run in
parallel across thousands of clonal populations.
- SpotLight™ Human Fc reagent binds to the Fc region of human
antibodies
- SpotLight™ Human Kappa reagent binds to the kappa light chain
of human antibodies
- Soon-to-be released SpotLight™ Human Lambda reagent binds to
the lambda light chain of human antibodies
As demonstrated by GSK, these reagents can be used individually
for screening of monospecific antibodies or in combination to
screen bispecific lambda-kappa antibodies.
Dr. Robyn Emmins, the Scientific
Director for Cell Line Development at GSK, commented: "The
SpotLight Human Lambda reagent further expands the range of
molecular formats we can screen using the Beacon; thus enabling a
flexible Cell Line Development process, to support our rapidly
diversifying Biopharmaceutical portfolio."
Please see the Opto® Cell Line Development
Workflow datasheet for additional information. The
SpotLight™ Human Lambda reagent will be available for purchase
after October 23, 2023.
About PhenomeX Inc.
PhenomeX is empowering scientists to leverage the full potential
of each cell and drive the next era of functional
cell biology that will advance human health. We enable
scientists to reveal the most complete insights on cell function
and obtain a full view of the behavior of each cell. Our unique
suite of proven high-throughput tools and services offer
unparalleled resolution and speed, accelerating the insights that
are key to advancing discoveries that can profoundly improve the
prevention and treatment of disease. Our award-winning
platforms are used by researchers across the globe, including those
at the top 15 global pharmaceutical companies and approximately 85%
of leading U.S. comprehensive cancer centers.
PhenomeX has no affiliation with Phenomenex, Inc. PhenomeX will
be changing its name. All inquiries regarding Phenomenex, Inc.
and/or its products should be directed
to info@phenomenex.com.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding PhenomeX or its
products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
PhenomeX undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company's growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phenomex-announces-the-release-of-spotlight-human-lambda-reagent-for-the-beacon-platform-to-accelerate-cell-line-development-workflows-301933719.html
SOURCE PhenomeX